Achieve Life Sciences (NASDAQ:ACHV) has been granted Breakthrough Therapy Designation from the FDA for cytisinicline as a potential treatment for addiction.

Safety Shot (NASDAQ: SHOT) has announced new data analysis from a recent clinical trial that shows significant validation for their proprietary drink.

Fentanyl testing company Safety Strips has entered into a letter of intent with Greenlane Holdings (NASDAQ:GNLN) to become the exclusive distributor in the USA.

Artificial intelligence powered drug discovery startup Enveda has raised $55 million in a Series B financing round.

Caladan Bio is developing next generation bioreactors that are capable of enhancing data capture and improving experimentation for synthetic biology companies.

Novo Nordisk (NASDAQ:NVO) has announced a new $600 million collaboration with Metaphore Biotechnologies to develop two new weight loss drug candidates.

CellVoyant is leveraging artificial intelligence and computer vision to develop new stem cell based therapeutics for chronic diseases.

BioAge Labs is developing a new type of weight loss drug that mimics the behaviour of a molecule that is typically naturally stimulated through exercise.

Biotechnology company Loyal has announced they have dosed their first ever dog in their clinical trial which aims to increase lifespan of older animals.

Wall Street and Silicon Valley have recently been making big new bets on potential breakthrough ways to treat obesity through novel therapeutics.